0001104659-17-041901.txt : 20170627 0001104659-17-041901.hdr.sgml : 20170627 20170627215451 ACCESSION NUMBER: 0001104659-17-041901 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170623 FILED AS OF DATE: 20170627 DATE AS OF CHANGE: 20170627 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics Plc CENTRAL INDEX KEY: 0001703287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 6108166640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Plc DATE OF NAME CHANGE: 20170407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Talbot George Harrison CENTRAL INDEX KEY: 0001554194 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38132 FILM NUMBER: 17933628 MAIL ADDRESS: STREET 1: C/O DURATA THERAPEUTICS, INC. STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 07960 4 1 a4.xml 4 X0306 4 2017-06-23 0 0001703287 Nabriva Therapeutics Plc NBRV 0001554194 Talbot George Harrison 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 0 0 0 Ordinary Shares 2017-06-23 5 J 0 E 31790 0 A 31790 D Stock Option 2017-06-23 5 J 0 E 40000 0 A 2025-07-05 Ordinary Shares 40000 40000 D Stock Option 2017-06-23 5 J 0 E 10100 0 A 2026-08-25 Ordinary Shares 10100 10100 D Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. This option was granted on July 6, 2015. Vesting began on July 31, 2015 and ends on July 31, 2019. Twenty-five percent (25%) of the option vested on July 31, 2016, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period. The exercise price is 6.618 Euro. This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. The exercise price is 6.634 Euro. /s/ George Harrison Talbot 2017-06-27